NCX-470 Emerging Drug Insight

“NCX-470, Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about NCX-470 for Glaucoma in the 7MM. A detailed picture of the NCX-470 for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the NCX-470 for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NCX-470 market forecast, analysis for Glaucoma in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently being developed by Nicox Ophthalmics is in Phase III of clinical study. It is being developed for treatment of open-angle glaucoma or ocular hypertension in the US.

NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy.

In November 2022, Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the NCX-470 description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on NCX-470 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the NCX-470 research and development activity in Glaucoma in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around NCX-470.
•  The report contains forecasted sales of NCX-470 for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for NCX-470 in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NCX-470 Analytical Perspective by DelveInsight

• In-depth NCX-470 Market Assessment

This report provides a detailed market assessment of NCX-470 in Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• NCX-470 Clinical Assessment

The report provides the clinical trials information of NCX-470 in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NCX-470 dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to NCX-470 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NCX-470 in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of NCX-470 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NCX-470 in Glaucoma.

Key Questions

•  What is the product type, route of administration and mechanism of action of NCX-470?
•  What is the clinical trial status of the study related to NCX-470 in Glaucoma and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NCX-470 development?
•  What are the key designations that have been granted to NCX-470 for Glaucoma?
•  What is the forecasted market scenario of NCX-470 for Glaucoma?
•  What are the forecasted sales of NCX-470 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Glaucoma and how are they giving competition to NCX-470 for Glaucoma?
•  Which are the late-stage emerging therapies under development for the treatment of Glaucoma?